Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2025-12-26 @ 2:22 AM
NCT ID:
NCT00925002
Pre Assignment Details:
Prior to B3461023, V30M participants completed 18 months (M) blinded treatment (placebo or tafamidis) in Fx-005 followed by 12M tafamidis in Fx-006; nonV30M participants completed 12M tafamidis in Fx1A-201. Baseline (except treatment-emergent adverse events) was last measurement prior to 1st dose in Fx-005 (V30M) or Fx1A-201 (NonV30M). V30M:data from Baseline to M18 from Fx-005; after M18 to M30 from Fx-006; after M30 from B3461023. NonV30M:Baseline to M12 from Fx1A-201, after M12 from B3461023.
Recruitment Details:
Participants enrolled in B3461023 had transthyretin amyloid polyneuropathy (ATTR-PN), had not undergone liver/heart transplantation, and completed either B3461021 (Fx-006 \[NCT00791492\]: extension to Fx-005 \[NCT00409175\]) or B3461022 (Fx1A-201 \[NCT00630864\]). Val30Met (V30M): valine replaced by methionine in position 30 of TTR protein; NonVal30Met (NonV30M): TTR mutations other than V30M.
Study:
NCT00925002
Study Brief:
Results Section:
NCT00925002